Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis
Year: 2023
Type: article
Abstract: BACKGROUND & AIMS: Obeticholic acid (OCA) is a first-in-class farnesoid X receptor agonist and antifibrotic agent in development for the treatment of pre-cirrhotic liver fibrosis due to non-alcoholic steatohepatitis (NASH). We aimed to validate the original 18-month liver biopsy analysis from the phase III REGENERATE trial of OCA for the treatment of NASH with a consensus panel analysis, provide additional histology data in a larger population, and evaluate safety from >8,000 total patient-years' exposure with nearly 1,000 participants receiving study drug for >4 years. METHODS: Digitized whole-slide images were evaluated independently by panels of three pathologists using the NASH Clinical Research Network scoring system. Primary endpoints were (1) ≥1 stage improvement in fibrosis with no worsening of NASH or (2) NASH resolution with no worsening of fibrosis. Safety was assessed by laboratory values and adverse events. RESULTS: Prespecified efficacy analyses included 931 participants. The proportion of participants achieving a ≥1 stage improvement in fibrosis with no worsening of NASH was 22.4% for OCA 25 mg vs. 9.6% for placebo (p <0.0001). More participants receiving OCA 25 mg vs. placebo achieved NASH resolution with no worsening of fibrosis (6.5% vs. 3.5%, respectively; p = 0.093). Histology data in a larger population of 1,607 participants supported these results. Safety data included 2,477 participants. The incidence of treatment-emergent adverse events (TEAEs), serious TEAEs, and deaths was not substantively different across treatment groups. Pruritus was the most common TEAE. Rates of adjudicated hepatic, renal, and cardiovascular events were low and similar across treatment groups. CONCLUSIONS: These results confirm the antifibrotic effect of OCA 25 mg. OCA was generally well tolerated over long-term dosing. These data support a positive benefit:risk profile in patients with pre-cirrhotic liver fibrosis due to NASH. IMPACT AND IMPLICATIONS: Patients with non-alcoholic steatohepatitis (NASH) often have liver scarring (fibrosis), which causes an increased risk of liver-related illness and death. Preventing progression of fibrosis to cirrhosis or reversing fibrosis are the main goals of drug development for NASH. In this clinical trial of obeticholic acid (OCA) in patients with NASH (REGENERATE), we reaffirmed our previous results demonstrating that OCA was superior to placebo in improving fibrosis using a more rigorous consensus panel analysis of liver biopsies taken at month 18. We also showed that OCA treatment resulted in dose-dependent reductions of serum liver biochemistries and liver stiffness measurements compared with placebo, even in participants in whom histologic fibrosis did not change at 18 months, providing evidence that the benefit of OCA extends beyond what is captured by the ordinal NASH CRN scoring system. OCA was well tolerated with a favorable safety profile supporting a positive benefit: risk profile in patients with pre-cirrhotic liver fibrosis due to NASH.
Source: Journal of Hepatology
Authors: Arun J. Sanyal, Vlad Ratziu, Rohit Loomba, Quentin M. Anstee, Kris V. Kowdley, Mary E. Rinella, Muhammad Y. Sheikh, James F. Trotter, Whitfield Knapple, Eric J. Lawitz, Manal F. Abdelmalek, Philip N. Newsome, Jérôme Boursier, Philippe Mathurin, Jean-François Dufour, M. Michelle Berrey, Steven J. Shiff, Sangeeta Sawhney, Thomas Capozza, Rina Leyva, Stephen A. Harrison, Zobair M. Younossi
Institutions: Virginia Commonwealth University, Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Fondation pour l’innovation en Cadiométabolisme et Nutrition, University of California San Diego, Newcastle upon Tyne Hospitals NHS Foundation Trust, NIHR Newcastle Biomedical Research Centre, Newcastle University, Liver Institute Northwest, University of Chicago, The University of Texas at San Antonio Health Science Center, Texas Liver Institute, Mayo Clinic, University Hospitals Birmingham NHS Foundation Trust, NIHR Birmingham Biomedical Research Centre, University of Birmingham, Université d'Angers, Centre Hospitalier Universitaire de Lille, Intercept Pharmaceuticals (United States), Pinnacle Clinical Research, Inova Health System
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,950
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Gilead Sciences, Alnylam Pharmaceuticals, Virginia Commonwealth University, Regeneron Pharmaceuticals, European Federation of Pharmaceutical Industries and Associations, University Hospitals Birmingham NHS Foundation Trust, Intercept Pharmaceuticals, NGM Biopharmaceuticals, National Institute for Health and Care Research, Department of Health and Social Care, Newcastle University, Newcastle upon Tyne Hospitals NHS Foundation Trust, Novo Nordisk, Genentech, Pritzker School of Medicine, Faculty of Medical Sciences, Newcastle University, Birmingham Biomedical Research Centre
OpenAlex ID: W4385337271
